The Center for Biosimilars® recaps the top news for the week of December 17, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 17.
Number 5: A real-world study has underscored the safety and effectiveness of Celltrion’s infliximab biosimilar, CT-P13, in patients with Crohn disease.
Number 4: A district court in Pennsylvania recently denied Johnson and Johnsons motion to dismiss the antitrust claim brought against the company by Walgreen and Kroger in regard to sales of J&J’s reference infliximab product, Remicade.
Number 3: Last week, insurer Cigna and pharmacy benefit manager Express Scripts overcame 2 hurdles to completing their 67-billion-dollar merger as New York and California insurance regulators signed off on the deal.
Number 2: Pfizer recently announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion of its proposed bevacizumab biosimilar.
Number 1: The FDA approved Celltrion and Teva’s biosimilar trastuzumab, Herzuma, for the treatment of HER2-positive breast cancer.
Finally, last week, our e-newsletter asked if the United States should rein in the number of patents it grants to drugs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.